Equity Details
Price & Market Data
Price: $2.48
Daily Change: -$0.09 / 3.63%
Daily Range: $2.45 - $2.62
Market Cap: $179,124,416
Daily Volume: 231,149
Performance Metrics
1 Week: -1.59%
1 Month: -1.20%
3 Months: 0.40%
6 Months: 31.91%
1 Year: 136.2%
YTD: 17.54%
About Acumen Pharmaceuticals, Inc. (ABOS)
Stay updated on Acumen Pharmaceuticals, Inc. (ABOS). Price: 2.48, daily change: -$0.09 / 3.63%. Market cap: 179,124,416. Performance YTD, 1-week, and 52-week are key.
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, and with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted EBDTM therapy for the treatment of Alzheimer's disease. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.